JP2019529541A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529541A5 JP2019529541A5 JP2019535191A JP2019535191A JP2019529541A5 JP 2019529541 A5 JP2019529541 A5 JP 2019529541A5 JP 2019535191 A JP2019535191 A JP 2019535191A JP 2019535191 A JP2019535191 A JP 2019535191A JP 2019529541 A5 JP2019529541 A5 JP 2019529541A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- composition
- additional therapeutic
- kit
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 20
- 210000003630 histaminocyte Anatomy 0.000 claims description 20
- 229940124597 therapeutic agent Drugs 0.000 claims description 20
- 230000000087 stabilizing effect Effects 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 17
- 208000035475 disorder Diseases 0.000 claims description 14
- 230000009385 viral infection Effects 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 8
- IYSYPCSSDZBWHN-UHFFFAOYSA-N Nor-ketotifen Chemical compound C1=2C=CSC=2C(=O)CC2=CC=CC=C2C1=C1CCNCC1 IYSYPCSSDZBWHN-UHFFFAOYSA-N 0.000 claims description 7
- 239000003443 antiviral agent Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 206010037660 Pyrexia Diseases 0.000 claims description 5
- 230000001754 anti-pyretic effect Effects 0.000 claims description 2
- 239000002221 antipyretic Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 7
- 206010022000 influenza Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical group CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims 3
- 229960003752 oseltamivir Drugs 0.000 claims 3
- 206010050685 Cytokine storm Diseases 0.000 claims 2
- 206010052015 cytokine release syndrome Diseases 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010022004 Influenza like illness Diseases 0.000 claims 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960004958 ketotifen Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662385021P | 2016-09-08 | 2016-09-08 | |
| US62/385,021 | 2016-09-08 | ||
| PCT/US2017/050409 WO2018048989A1 (en) | 2016-09-08 | 2017-09-07 | Mast cell stabilizers for treatment of hypercytokinemia and viral infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019529541A JP2019529541A (ja) | 2019-10-17 |
| JP2019529541A5 true JP2019529541A5 (enExample) | 2020-10-08 |
Family
ID=61281984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019535191A Pending JP2019529541A (ja) | 2016-09-08 | 2017-09-07 | 高サイトカイン血症及びウィルス感染の処置の為の肥満細胞安定剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US10501527B2 (enExample) |
| EP (1) | EP3509596B1 (enExample) |
| JP (1) | JP2019529541A (enExample) |
| KR (1) | KR20190073365A (enExample) |
| CN (1) | CN109952101A (enExample) |
| AU (2) | AU2017325010A1 (enExample) |
| BR (1) | BR112019004496A2 (enExample) |
| CA (1) | CA3036230A1 (enExample) |
| ES (1) | ES2988617T3 (enExample) |
| IL (1) | IL265208A (enExample) |
| MX (1) | MX389999B (enExample) |
| MY (1) | MY204310A (enExample) |
| PH (1) | PH12019500513A1 (enExample) |
| RU (1) | RU2760682C2 (enExample) |
| WO (1) | WO2018048989A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| KR20190044647A (ko) | 2016-08-31 | 2019-04-30 | 더 제너럴 하스피탈 코포레이션 | 신경변성 질환과 관련된 신경-염증에서 대식세포/미세아교세포 |
| KR20190073365A (ko) | 2016-09-08 | 2019-06-26 | 이메르고 테라퓨틱스, 인코포레이티드 | 사이토카인 과분비 및 바이러스성 감염의 치료를 위한 비만 세포 안정화제 |
| JP2019533018A (ja) | 2016-10-18 | 2019-11-14 | エマーゴ セラピューティクス，インク． | 慢性炎症状態の処置の為の肥満細胞安定剤 |
| WO2020051322A1 (en) * | 2018-09-05 | 2020-03-12 | The General Hospital Corporation | Methods of treating cytokine release syndrome |
| CA3122989A1 (en) | 2018-12-10 | 2020-06-18 | The General Hospital Corporation | Cromolyn esters and uses thereof |
| US20200268734A1 (en) * | 2019-02-22 | 2020-08-27 | Bridge Pharma, Inc. | Methods of treatment of respiratory disorders |
| US10959992B2 (en) | 2019-02-22 | 2021-03-30 | Bridge Pharma Inc. | Methods of treatment of asthma and COPD |
| US20230346848A1 (en) * | 2020-03-06 | 2023-11-02 | Figene, Llc | Fibroblast and tlr activated fibroblast treatment of viral induced acute respiratory distress syndrome |
| JP2023520580A (ja) * | 2020-04-06 | 2023-05-17 | ザ ジェネラル ホスピタル コーポレイション | コロナウイルス誘発炎症状態の処置方法 |
| WO2023278381A1 (en) * | 2021-06-29 | 2023-01-05 | Bridge Pharma, Inc. | Treatment of dermal cytokine storm syndromes |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6878715B1 (en) | 1994-02-18 | 2005-04-12 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same |
| AU6165798A (en) | 1997-02-18 | 1998-09-08 | Bridge Pharma, Inc. | Non-sedating histamine antagonist compounds, compositions and methods of use thereof |
| BR9807911A (pt) | 1997-04-03 | 2000-02-22 | Bridge Pharma Inc | Compostos benzocicloheptatiofeno |
| US6207684B1 (en) * | 1997-06-09 | 2001-03-27 | Bridge Pharma, Inc. | Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use |
| CA2283603A1 (en) | 1998-10-01 | 2000-04-01 | Paul W. Behnke | Forced closed-loop cooling for a submersible pump motor |
| AU782816B2 (en) | 1999-09-13 | 2005-09-01 | Bridge Pharma, Inc. | Optically active isomers of ketotifen and therapeutically active metabolites thereof |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US20050249735A1 (en) | 2000-08-07 | 2005-11-10 | Centocor, Inc. | Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US20030118670A1 (en) * | 2001-07-11 | 2003-06-26 | Smith C. Steven | Novel composition and method for altering allergenic protein in the environment |
| US6680299B2 (en) | 2001-07-27 | 2004-01-20 | Enanta Pharmaceuticals, Inc. | 4'-substituted leucomycins |
| US20060084695A1 (en) | 2004-04-29 | 2006-04-20 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
| JP2009517404A (ja) | 2005-11-28 | 2009-04-30 | メディミューン，エルエルシー | Ｈｍｇｂ１および／またはｒａｇｅのアンタゴニストならびにその使用方法 |
| CN104614873A (zh) | 2006-09-29 | 2015-05-13 | 庄臣及庄臣视力保护公司 | 用于治疗眼变态反应性的方法和眼科装置 |
| US20080139531A1 (en) | 2006-12-04 | 2008-06-12 | Alcon Manufacturing Ltd. | Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair |
| WO2008153761A1 (en) * | 2007-05-23 | 2008-12-18 | Mastcell Pharmaceuticals, Inc. | Methods |
| EP2214503A1 (en) | 2007-10-15 | 2010-08-11 | Revolymer Limited | Solvent-free synthesis of amphiphilic polymeric material |
| CN101821989A (zh) | 2007-12-24 | 2010-09-01 | 中兴通讯股份有限公司 | 一种光传输系统的通道共享保护方法及装置 |
| CN101990437A (zh) * | 2008-01-04 | 2011-03-23 | 阿尔康药品有限公司 | 稳定的环孢菌素水性组合物 |
| WO2009142772A2 (en) | 2008-05-23 | 2009-11-26 | Mastcell Pharmaceuticals, Inc. | Methods and treatment for allergies and inflammation associated with gastrointestinal diseases |
| US8741930B2 (en) | 2008-10-24 | 2014-06-03 | Bridge Pharma, Inc. | Treating xerophthalmia with norketotifen |
| WO2010059894A1 (en) | 2008-11-21 | 2010-05-27 | Bridge Pharma, Inc. | Ocular formulations of norketotifen |
| CA2754996A1 (en) | 2009-03-17 | 2010-09-23 | Aciex Therapeutics, Inc. | Ophthalmic formulations of ketotifen and methods of use |
| WO2010106016A1 (en) | 2009-03-17 | 2010-09-23 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
| CA2780453A1 (en) | 2009-12-02 | 2011-06-09 | Bridge Pharma, Inc. | Treating xerophthalmia with compounds increasing meibomian gland secretion |
| HUE033063T2 (hu) | 2010-05-14 | 2017-11-28 | Abbvie Inc | IL-1 kötõ fehérjék |
| UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| JP2014520847A (ja) | 2011-07-13 | 2014-08-25 | アッヴィ・インコーポレイテッド | 抗ｉｌ−１３抗体を使用して喘息を治療するための方法および組成物 |
| WO2014040112A1 (en) | 2012-09-17 | 2014-03-20 | Guina Research & Development Pty Ltd | Electromagnetic turbine |
| US8557846B1 (en) | 2012-10-23 | 2013-10-15 | Bridge Pharma, Inc. | Medicinal treatment of dermal diseases in dogs |
| US8778971B2 (en) | 2012-10-23 | 2014-07-15 | Bridge Pharma, Inc. | Medicinal treatment of dermal diseases in companion animals |
| US20140120121A1 (en) | 2012-10-30 | 2014-05-01 | Bridge Pharma, Inc. | Medicinal treatment of atopic inflammatory diseases |
| US20150272941A1 (en) | 2012-10-30 | 2015-10-01 | Bridge Pharma, Inc. | Medicinal treatment of chronic pulmonary inflammatory diseases with norketotifen |
| US9347325B2 (en) | 2012-10-31 | 2016-05-24 | Solar Turbines Incorporated | Damper for a turbine rotor assembly |
| JP6084473B2 (ja) | 2013-02-01 | 2017-02-22 | 日立オートモティブシステムズ株式会社 | 複合センサ |
| US9439895B2 (en) | 2013-08-06 | 2016-09-13 | Bridge Pharma, Inc. | Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients |
| US9345697B2 (en) | 2013-08-06 | 2016-05-24 | Bridge Pharma, Inc. | Methods of treatment of non-histaminic pruritus |
| US9138431B2 (en) * | 2013-08-06 | 2015-09-22 | Bridge Pharma, Inc. | Methods of treatment of histamine H-4 receptor-related pruritus |
| WO2015120389A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Mast cell stabilizers treatment for systemic disorders |
| US10293352B2 (en) | 2015-02-13 | 2019-05-21 | Kärcher North America, Inc. | Hand held fluid dispensing apparatus |
| CA2976369A1 (en) | 2015-02-13 | 2016-08-18 | Yale University | Biaryltriazole inhibitors of macrophage migration inhibitory factor |
| WO2017035418A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for treatment of immune and inflammatory disorders |
| US9694003B2 (en) | 2015-10-15 | 2017-07-04 | Bridge Pharma, Inc. | Formulations and methods for treating high intraocular pressure |
| KR20190073365A (ko) | 2016-09-08 | 2019-06-26 | 이메르고 테라퓨틱스, 인코포레이티드 | 사이토카인 과분비 및 바이러스성 감염의 치료를 위한 비만 세포 안정화제 |
| JP2019533018A (ja) | 2016-10-18 | 2019-11-14 | エマーゴ セラピューティクス，インク． | 慢性炎症状態の処置の為の肥満細胞安定剤 |
-
2017
- 2017-09-07 KR KR1020197010083A patent/KR20190073365A/ko not_active Ceased
- 2017-09-07 WO PCT/US2017/050409 patent/WO2018048989A1/en not_active Ceased
- 2017-09-07 BR BR112019004496A patent/BR112019004496A2/pt not_active Application Discontinuation
- 2017-09-07 MY MYPI2019000588A patent/MY204310A/en unknown
- 2017-09-07 MX MX2019002781A patent/MX389999B/es unknown
- 2017-09-07 CA CA3036230A patent/CA3036230A1/en active Pending
- 2017-09-07 ES ES17849505T patent/ES2988617T3/es active Active
- 2017-09-07 CN CN201780068796.6A patent/CN109952101A/zh active Pending
- 2017-09-07 EP EP17849505.7A patent/EP3509596B1/en active Active
- 2017-09-07 AU AU2017325010A patent/AU2017325010A1/en not_active Abandoned
- 2017-09-07 US US15/697,835 patent/US10501527B2/en active Active
- 2017-09-07 JP JP2019535191A patent/JP2019529541A/ja active Pending
- 2017-09-07 RU RU2019110150A patent/RU2760682C2/ru active
- 2017-11-17 US US15/816,461 patent/US10160796B2/en active Active
-
2018
- 2018-11-15 US US16/192,385 patent/US10494420B2/en active Active
-
2019
- 2019-03-07 IL IL265208A patent/IL265208A/en unknown
- 2019-03-08 PH PH12019500513A patent/PH12019500513A1/en unknown
- 2019-10-25 US US16/664,037 patent/US10787502B2/en active Active
- 2019-10-25 US US16/664,039 patent/US11072648B2/en active Active
-
2023
- 2023-06-23 AU AU2023204000A patent/AU2023204000A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529541A5 (enExample) | ||
| RU2019110150A (ru) | Стабилизаторы тучных клеток лечения гиперцитокинемии и вирусной инфекции | |
| JP2023002662A5 (enExample) | ||
| JP2017526716A5 (enExample) | ||
| JP2018193377A5 (enExample) | ||
| JP2018048154A5 (enExample) | ||
| JP2018518537A5 (enExample) | ||
| JP2020512337A5 (enExample) | ||
| JP2018505882A5 (enExample) | ||
| JP2019510079A5 (enExample) | ||
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| JP2018513188A5 (enExample) | ||
| JP2013500977A5 (enExample) | ||
| JP2013509441A5 (enExample) | ||
| JP2016027060A5 (enExample) | ||
| JP2019520344A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| JP2017522300A5 (enExample) | ||
| JP2018172440A5 (enExample) | ||
| JP2017014206A5 (enExample) | ||
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| JP2016537338A5 (enExample) | ||
| JP2017515840A5 (enExample) | ||
| WO2018005794A3 (en) | Novel non-systemic tgr5 agonists |